539 related articles for article (PubMed ID: 27987240)
21. Dapagliflozin in the treatment of patients with type 2 diabetes presenting with high baseline A1C.
Skolnik N; Bonnes H; Yeh H; Katz A
Postgrad Med; 2016 May; 128(4):356-63. PubMed ID: 27043045
[TBL] [Abstract][Full Text] [Related]
22. Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS).
Terauchi Y; Tamura M; Senda M; Gunji R; Kaku K
Diabetes Obes Metab; 2018 May; 20(5):1176-1185. PubMed ID: 29316236
[TBL] [Abstract][Full Text] [Related]
23. A multicentre, double-blind, placebo-controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add-on therapy in type 2 diabetic patients treated with metformin and dapagliflozin.
Lim S; Lee SH; Min KW; Lee CB; Kim SY; Yoo HJ; Kim NH; Kim JH; Oh S; Won JC; Kwon HS; Kim MK; Park JH; Jeong IK; Kim S
Diabetes Obes Metab; 2024 Jun; 26(6):2188-2198. PubMed ID: 38425186
[TBL] [Abstract][Full Text] [Related]
24. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.
Ji L; Ma J; Li H; Mansfield TA; T'joen CL; Iqbal N; Ptaszynska A; List JF
Clin Ther; 2014 Jan; 36(1):84-100.e9. PubMed ID: 24378206
[TBL] [Abstract][Full Text] [Related]
25. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin.
Nauck MA; Del Prato S; Durán-García S; Rohwedder K; Langkilde AM; Sugg J; Parikh SJ
Diabetes Obes Metab; 2014 Nov; 16(11):1111-20. PubMed ID: 24919526
[TBL] [Abstract][Full Text] [Related]
26. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial.
Bailey CJ; Gross JL; Hennicken D; Iqbal N; Mansfield TA; List JF
BMC Med; 2013 Feb; 11():43. PubMed ID: 23425012
[TBL] [Abstract][Full Text] [Related]
27. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
[TBL] [Abstract][Full Text] [Related]
28. Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin.
Del Prato S; Rosenstock J; Garcia-Sanchez R; Iqbal N; Hansen L; Johnsson E; Chen H; Mathieu C
Diabetes Obes Metab; 2018 Jun; 20(6):1542-1546. PubMed ID: 29446523
[TBL] [Abstract][Full Text] [Related]
29. Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial.
Schumm-Draeger PM; Burgess L; Korányi L; Hruba V; Hamer-Maansson JE; de Bruin TW
Diabetes Obes Metab; 2015 Jan; 17(1):42-51. PubMed ID: 25200570
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.
Rosenstock J; Seman LJ; Jelaska A; Hantel S; Pinnetti S; Hach T; Woerle HJ
Diabetes Obes Metab; 2013 Dec; 15(12):1154-60. PubMed ID: 23906374
[TBL] [Abstract][Full Text] [Related]
31. Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus.
Araki E; Tanizawa Y; Tanaka Y; Taniguchi A; Koiwai K; Kim G; Salsali A; Woerle HJ; Broedl UC
Diabetes Obes Metab; 2015 Jul; 17(7):665-74. PubMed ID: 25772548
[TBL] [Abstract][Full Text] [Related]
32. Long-term (52-week) efficacy and safety of dapagliflozin as an adjunct to insulin therapy in Japanese patients with type 1 diabetes: Subgroup analysis of the DEPICT-2 study.
Araki E; Mathieu C; Shiraiwa T; Maeda H; Ikeda H; Thoren F; Arya N; Asano M; Iqbal N
Diabetes Obes Metab; 2021 Jul; 23(7):1496-1504. PubMed ID: 33620762
[TBL] [Abstract][Full Text] [Related]
33. Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial.
Vilsbøll T; Ekholm E; Johnsson E; Dronamraju N; Jabbour S; Lind M
Diabetes Care; 2019 Aug; 42(8):1464-1472. PubMed ID: 31167892
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial.
Kaku K; Inoue S; Matsuoka O; Kiyosue A; Azuma H; Hayashi N; Tokudome T; Langkilde AM; Parikh S
Diabetes Obes Metab; 2013 May; 15(5):432-40. PubMed ID: 23194084
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.
Dandona P; Mathieu C; Phillip M; Hansen L; Griffen SC; Tschöpe D; Thorén F; Xu J; Langkilde AM;
Lancet Diabetes Endocrinol; 2017 Nov; 5(11):864-876. PubMed ID: 28919061
[TBL] [Abstract][Full Text] [Related]
36. Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial.
Jabbour SA; Frías JP; Hardy E; Ahmed A; Wang H; Öhman P; Guja C
Diabetes Care; 2018 Oct; 41(10):2136-2146. PubMed ID: 30082326
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise.
Kaku K; Kiyosue A; Inoue S; Ueda N; Tokudome T; Yang J; Langkilde AM
Diabetes Obes Metab; 2014 Nov; 16(11):1102-10. PubMed ID: 24909293
[TBL] [Abstract][Full Text] [Related]
38. Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time.
Parikh S; Wilding J; Jabbour S; Hardy E
Int J Clin Pract; 2015 Feb; 69(2):186-98. PubMed ID: 25438821
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
Kadowaki T; Kondo K
Diabetes Obes Metab; 2014 May; 16(5):418-25. PubMed ID: 24205974
[TBL] [Abstract][Full Text] [Related]
40. [Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride].
Strojek K; Yoon KH; Hruba V; Elze M; Langkilde AM; Parikh S
Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S16-26. PubMed ID: 23529567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
